The Cell & Gene Therapy Innovation Center (CGTIC) is a research and development platform dedicated to cell and gene therapy, established by the Beijing Tsinghua Industrial R&D Institute with the support of Beijing Municipal Science and Technology Commission and Changping District. It collaborates with top domestic and international biopharmaceutical research institutions and emerging enterprises. Beijing LotusLake BioMedical Technology Co., Ltd. serves as the main operator of CGTIC, undertaking the operational management of the center. CGTIC is located in the Life Science Park of Changping District, Beijing, covering an area of about 15,000 square meters. It includes 10 complete GMP production lines that comply with standards from China, the United States, and Europe. CGTIC is capable of highly flexible co-line production for a variety of drugs, including mRNA, cell therapy, and gene therapy, with its batch production capacity ranking among the top in the nation. Additionally, CGTIC relies on the innovation system of the Beijing Tsinghua Industrial R&D Institute and works in conjunction with supply chain partners to achieve a new industrialized definition and design. On this foundation, CGTIC has constructed a new "short process" development paradigm for the cell and gene therapy industry, characterized by "fast R&D, fast production, fast clinical".